Get the Stockscreener App
1.88
1.57%
-0.03
After Hours:
1.91
0.03
+1.60%
Biomea Fusion Inc stock is traded at $1.88, with a volume of 629.65K.
It is down -1.57% in the last 24 hours and down -35.17% over the past month.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
See More
Previous Close:
$1.91
Open:
$1.9
24h Volume:
629.65K
Relative Volume:
0.27
Market Cap:
$70.64M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-0.4688
EPS:
-4.01
Net Cash Flow:
$-113.02M
1W Performance:
-2.59%
1M Performance:
-35.17%
6M Performance:
-52.70%
1Y Performance:
-64.66%
1-Day Range:
$1.87
$1.965
1-Week Range:
$1.77
$2.01
52-Week Range:
$1.2905
$13.07
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
900 MIDDLEFIELD ROAD, REDWOOD CITY
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.88 | 110.05M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
What makes Biomea Fusion Inc. stock price move sharplyFree Best Performing Stock Alerts - Newser
How Biomea Fusion Inc. stock performs during market volatilityProfitable Yet Secure Picks - Newser
Why Biomea Fusion Inc. stock attracts strong analyst attentionFree Market Analysis Group - Newser
While institutions invested in Biomea Fusion, Inc. (NASDAQ:BMEA) benefited from last week's 15% gain, retail investors stood to gain the most - Yahoo
Want to make yourself less appealing to mosquitoes? Our quiz has surprising ideas - Alaska Public Media
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Biomea Fusion’s BMF-219 Study Update: Implications for Investors - TipRanks
Biomea Fusion’s BMF-219 Study: A Potential Game-Changer for Type 2 Diabetes - TipRanks
Oppenheimer & Co. Inc. Buys 78,579 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion’s Phase 2 Trial: A New Hope for Type 1 Diabetes Treatment - TipRanks
Biomea Fusion, Inc.(NasdaqGS: BMEA) dropped from Russell 2000 Index - MarketScreener
Biomea Fusion, Inc.(NasdaqGS: BMEA) added to Russell Microcap Value Index - MarketScreener
HC Wainwright Predicts Stronger Earnings for Biomea Fusion - Defense World
Exchange Traded Concepts LLC Grows Stock Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (CDTX), Hims & Hers Health (HIMS) and Biomea Fusion (BMEA) - The Globe and Mail
Diabetes Drug Trial Shows 55% C-Peptide Boost, Enhanced GLP-1 Results | BMEA Stock News - Stock Titan
Biomea Fusion Closes $37.1M Stock Offering - TipRanks
Biomea Fusion stock falls after announcing public offering By Investing.com - Investing.com Australia
Market Today: Safran's Asset Sale and Biomea Fusion's Stock Offering - GuruFocus
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Top Midday Decliners - MarketScreener
Biomea Fusion (BMEA) Reports Promising Preclinical Results for W - GuruFocus
Bitdeer, Biomea Fusion, Circle Internet - TradingView
Biomea Fusion (BMEA) Reports Promising Preclinical Results for Weight Loss Study | BMEA Stock News - GuruFocus
Biomea Fusion Reports Preclinical Data for BMF-650, a - GlobeNewswire
Biomea Fusion (BMEA) Receives Reaffirmed Buy Rating by D. Boral Capital | BMEA Stock News - GuruFocus
Biomea Fusion surges 76% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates - Yahoo Finance
US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity - Benzinga
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Biomea Fusion tumbles on deep-discounted $40 mln equity raise - TradingView
Biomea Fusion Prices $40 Million Offering of Securities - marketscreener.com
Biomea Fusion (BMEA) Launches Public Offering with Warrants | BM - GuruFocus
Biomea Fusion (BMEA) Launches $40M Public Offering, Shares Drop - GuruFocus
Biomea Fusion sinks 25%, prices $40M stock offering (BMEA:NASDAQ) - Seeking Alpha
Diabetes Drug Developer Biomea Fusion Raises $40M in Strategic Public Offering with Warrant Sweetener - Stock Titan
(BMEA) Faces Pricing Challenge with New Offering | BMEA Stock News - GuruFocus
Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead - Asianet Newsable
Biomea Fusion Announces Pricing Of Public Offering Of Securities - marketscreener.com
Biomea Fusion Announces Pricing of Public Offering of Securities - GlobeNewswire Inc.
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com India
Biomea Fusion Launches Public Offering of Securities; Shares Fall After Hours - marketscreener.com
Biomea Fusion tumbles on planned equity offering - TradingView
Biomea Fusion launches public offering of common stock and warrants - Investing.com
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants - Nasdaq
Biomea Fusion Launches Major Public Offering with Jefferies to Advance Diabetes and Obesity Programs - Stock Titan
Biomea Fusion stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Purchased by Bank of America Corp DE - Defense World
D. Boral Capital Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) Receives Continued - GuruFocus
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):